21st week of 2015 patent applcation highlights part 60 |
Patent application number | Title | Published |
20150141295 | SOLID-PHASE CLONAL AMPLIFICATION AND RELATED METHODS - The present invention provides methods and compositions for analyzing nucleic acid sequences. In some aspects, the methods utilize clonal objects, such as DNA balls, that have been captured on beads. Using the methods described here, compositions are fabricated wherein a bead and one clonal object are affinity bound or hybridized to each other through an affinity binding patch or hybridization patch on the surface of the bead. The invention also provides a population of beads having affinity bound or hybridized clonal objects at a ratio of 1:1. The invention additionally provides methods for amplifying a target nucleic acid molecule utilizing the compositions described herein. | 2015-05-21 |
20150141296 | METHODS FOR PERFORMING PATTERNED CHEMISTRY - Provided are methods for performing patterned chemistry and arrays prepared thereby. | 2015-05-21 |
20150141297 | Methods and Compositions for Phototransfer - Methods are described for phototransferring a compound from a first surface to a second surface. Compounds are described with photocleavable linkers. Compounds attached to a first surface through a photocleavable linker are put in proximity (or contact) with a second surface, and then phototransferred to the second surface upon exposure to electromagnetic radiation. Illuminating the compound with radiation photocleaves the compound from the first surface and transfers the compound to the second surface. | 2015-05-21 |
20150141298 | METHOD OF MANUFACTURING PROBE-IMMOBILIZED CARRIER - A probe-immobilized carrier for detecting a target substance is manufactured such that a spot is prevented from being contaminated with another spot and a probe is prevented from nonspecifically adsorbing a background area in the manufacture of the probe-immobilized carrier and nonspecific adsorption cannot be occurred even after the formation of an array. A substrate containing a reactive group for immobilizing a probe thereon is used and the steps of: (i) supplying a liquid droplet containing a probe on the substrate; (ii) inactivating a reactive group existing in an area other than a supplying area of the substrate, and (iii) removing an unreacted probe existing in the supplied liquid droplet are carried out. | 2015-05-21 |
20150141299 | FABRICATING SELF-FORMED NANOMETER PORE ARRAY AT WAFER SCALE FOR DNA SEQUENCING - A technique is provided for a structure. A substrate has a nanopillar vertically positioned on the substrate. A bottom layer is formed beneath the substrate. A top layer is formed on top of the substrate and on top of the nanopillar, and a cover layer covers the top layer and the nanopillar. A window is formed through the bottom layer and formed through the substrate, and the window ends at the top layer. A nanopore is formed through the top layer by removing the cover layer and the nanopillar. | 2015-05-21 |
20150141300 | FLUOROUS ADDITIVES FOR USE IN A FLUOROUS-BASED TREATMENT FLUID - A treatment fluid comprises: a liquid fluorinated compound; and at least one additive, wherein the additive: (A) comprises carbon and at least one fluorine functional group; and (B) is soluble or dispersible in the liquid fluorinated compound. A method of treating a portion of a well comprises: forming the treatment fluid; and introducing the treatment fluid into the well. | 2015-05-21 |
20150141301 | PERACETIC ACID OIL-FIELD BIOCIDE AND METHOD - Aqueous well treatment fluid compositions with biocidal activity are disclosed comprising a polymer for modifying fluid viscosity in the aqueous fluid, an organic monocarboxylic peracid being present in an anti-microbial amount of about 1 ppm to about 1000 ppm, and a controlled amount of hydrogen peroxide also being present. Peracetic acid is the preferred peracid. The viscosity-modifying polymer in the aqueous well treatment fluid composition may serve to reduce friction in the fluid or increase fluid viscosity. A method of using such compositions is also disclosed. | 2015-05-21 |
20150141302 | Composition Containing An Emulsified Chelating Agent And Process To Treat A Subterreanean Formation - The present invention relates to a composition containing a dispersed phase emulsified in a continuous phase, wherein at least 5 wt % on total weight of the dispersed phase of the composition is a chelating agent selected from the group of glutamic acid N,N-diacetic acid or a salt thereof (GLDA), aspartic acid N,N-diacetic acid or a salt thereof (ASDA), and methylglycine N,N-diacetic acid or a salt thereof (MGDA), and a process for treating a subterranean formation comprising a step of introducing the above composition into the formation. | 2015-05-21 |
20150141303 | BINARY AND TERNARY SURFACTANT BLENDS FOR ENHANCED OIL RECOVERY IN RESERVOIR BRINES WITH EXTREMELY HIGH TOTAL DISSOLVED SOLIDS - A binary or ternary surfactant mixture for use in enhanced oil recovery within a reservoir having total dissolved solids greater than approximately 80,000 parts per million (i.e., heavy to extreme brine conditions) includes at least two of a propoxylated/ethoxylated alcohol sulfate, an ethoxylated alcohol sulfate, and a monoalkyl or dialkyl diphenyloxide disulfonate. The surfactant mixture is used without alcohol, which is unnecessary to maintain solution stability and good coalescence rates and thus improves compatibility with polymers added to improve the mobility ratio. During testing, exceptional solution stability, excellent oil recovery capability, and good compatibility was observed with these surfactant blends. The mixtures are effective at concentrations below 1% and as low as 0.1% by weight. | 2015-05-21 |
20150141304 | Low-Density Downhole Fluids and Uses Thereof - A downhole fluid may be circulated within a wellbore where the downhole fluid may include at least a modified perlite and/or an aerogel. The amount of the modified perlite and/or aerogel within the downhole fluid may range from about 5 vol % to about 30 vol % of the downhole fluid of the total amount of the downhole fluid. The downhole fluid may be a drilling fluid, completion fluid, lost circulation pill, displacement pill, and combinations thereof. The material may help the downhole fluid maintain a relatively low density of less than about 1100 kg/m | 2015-05-21 |
20150141305 | LUBRICATING OIL COMPOSITION FOR CONTINUOUSLY VARIABLE TRANSMISSION - A lubricating oil composition for a continuously variable transmission has low viscosity to exhibit fuel savings, higher metal-to-metal friction coefficient to ensure high power transmission, wet clutch friction characteristics and anti-shudder properties required for transmissions, and low traction coefficient to achieve fuel savings. The composition contains a base oil adjusted so the product (EC×V40) of the mass % (ECmass %) of saturated cyclic component based on the total base oil and the 40° C. kinematic viscosity (V40 mm | 2015-05-21 |
20150141306 | Friction Modifiers for Slideway Applications - A slideway lubricating oil composition, additive concentrate, method of lubricating sliding parts. The lubricating oil includes a base oil; a metal-free friction modifier; and a metal-free, sulfur-free, phosphorus containing anti-wear/extreme pressure agent. The lubricating oil provides a lower coefficient of friction for non-metal sliding surfaces than for metal sliding surfaces. | 2015-05-21 |
20150141307 | Lubricating Composition Containing a Salt of a Carboxylic Acid - The invention provides a lubricating composition containing an oil of lubricating viscosity and an amine or ammonia salt of a carboxylic acid compound where said carboxylic acid is characterized in that it is functionalized with a hydroxy-substituted aromatic moiety. The invention further relates to methods of lubricating an internal combustion engine by supplying the described lubricating composition to the internal combustion engine. The invention further relates to the use of the salt of the carboxylic acid compound as an antiwear agent or an antioxidant. | 2015-05-21 |
20150141308 | Energy Efficient Polyalkylene Glycols and Lubricant Composition Containing Same - A polyalkylene glycol comprising: a random copolymer comprising units derived from EO and units derived from PO initiated with polytetrahydrofuran; wherein the polyalkylene glycol has a pour point of less than or equal to −30° C. as measured using ASTM D97 and a traction value of less than 0.0165 at a contact pressure of 1.25 GPa, speed=2 m/s, SRR of 100% and temperature of 80° C. is provided. Also provided are lubricant compositions containing such polyalkylene glycol. | 2015-05-21 |
20150141309 | FABRIC SOFTENER COMPOSITION - A fabric softener composition comprising a fabric softener active, a perfume oil, and from 0.4% to 0.9%, by weight of the composition, of an amphiphile compound. The fabric softener composition delivers improved physical stability across a broad temperature range without compromising its fabric softening properties. | 2015-05-21 |
20150141310 | PERFUME SYSTEMS - The present application relates to perfume raw materials, perfume delivery systems and consumer products comprising such perfume raw materials and/or such perfume delivery systems, as well as processes for making and using such perfume raw materials, perfume delivery systems and consumer products. Such perfume raw materials and compositions, including the delivery systems, disclosed herein expand the perfume communities' options as such perfume raw materials can provide variations on character and such compositions can provide desired odor profiles. | 2015-05-21 |
20150141311 | CLEANING COMPOSITIONS AND METHODS FOR BURNT-ON FOOD AND OIL RESIDUES - Disclosed herein are compositions comprising a solubilizing agent for the removal of burnt-on, cooked-on, baked-on, dried-on and charred organic food and oil residues from surfaces comprising alcohol, a coupling agent, water, an anti-deposition agent, a pH buffer and a surfactant system that preferably includes a fermentation supernatant, where the supernatant contains essentially stress proteins. Further enclosed are methods of cleaning for ovens, industrial cooking equipment and the like. | 2015-05-21 |
20150141312 | Discrete Or Single Dose Detergent Formulation - Discrete or single dose detergent formulation | 2015-05-21 |
20150141313 | CLEANING CAPSULE - The invention is related to a cleaning capsule for admission to the inner part of a hot beverage system, in particular a coffee machine, whose hollow space contains a cleaning material. The cleaning capsule contains in the hollow space an inert filling material in addition to the cleaning material. | 2015-05-21 |
20150141314 | THIOPHENE AZO DYES AND LAUNDRY CARE COMPOSITIONS CONTAINING THE SAME - This application relates to thiophene azo dyes for use as hueing agents, laundry care compositions comprising such thiophene azo dyes, processes for making such thiophene azo dyes, and laundry care compositions and methods of using the same. The thiophene azo dyes contain a formally charged moiety and are generally comprised of at least two components: at least one chromophore component and at least one polymeric component. Suitable chromophore components generally fluoresce blue, red, violet, or purple color when exposed to ultraviolet light, or they may absorb light to reflect these same shades. These thiophene azo dyes are advantageous in providing a hueing effect, for example, a whitening effect to fabrics, while not building up over time and causing undesirable blue discoloration to the treated fabrics. The thiophene azo dyes are also generally stable to bleaching agents used in laundry care compositions. | 2015-05-21 |
20150141315 | Method to recover or increase water absorbency of polyester textile - The present invention concerns then a method to recover or increase the water absorbency of a polyester textile, wherein a composition comprising at least a polyester soil release polymer and a quaternary ammonium softener is used to wash and/or rinse said polyester textile. This composition of the invention may be perfectly used during the water cycle(s) of the laundry or in the rinse cycle(s), notably used in the final rinse. The invention concerns as well a softener composition, notably used in the rinsing cycles of the laundry, comprising a polyester soil release polymer and a quaternary ammonium softener. | 2015-05-21 |
20150141316 | VARIANT ALPHA AMYLASES WITH ENHANCED ACTIVITY ON STARCH POLYMERS - Described are variants of alpha-amylase enzymes for use in industrial processes, such as liquefaction of starch. The alpha-amylase variants have increased specific activity allowing the more rapidly reduction of peak viscosity during liquefaction processes. The alpha-amylase is modified by introducing into the amino sequence of a parent Family 13 alpha-amylase polypeptide a mutation at an amino acid residue in the starch-binding groove; wherein the starch-binding groove is formed by amino acid residues in the alpha-helix preceding the first beta-strand in the A domain, the loop between the sixth alpha-helix and the seventh beta-strand in the A domain, the loop between the seventh alpha-helix and the eighth beta-strand in the A domain, and the loop connecting the A domain and the C domain; and wherein the mutation alters the binding of starch to the variant alpha amylase polypeptide compared to the parental alpha amylase polypeptide. | 2015-05-21 |
20150141317 | BRIGHT DETERGENT COMPOSITION - A coloured laundry detergent is provided that brightens on exposure to light. | 2015-05-21 |
20150141318 | USE OF SUGARS IN A STABILIZATION MATRIX AND SOLID COMPOSITIONS - The use of sugars in a stabilization matrix and solid detergent compositions is disclosed along with methods of making and using the solid detergent compositions. | 2015-05-21 |
20150141319 | POLYMERIC COMPOSITIONS FOR SUSTAINED RELEASE OF VOLATILE MATERIALS - A polymeric composition comprising a copolymer of ethylene with at least another monomer comprising at least a heteroatom, a tackifier, less than 10% of a compatible plasticizer or blend of plasticizers and a volatile material. The compositions are able to deliver effectively the volatile material incorporated for a long time and also have good adhesion properties on most substrates. | 2015-05-21 |
20150141320 | COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION - Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of a target gene. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of a target gene. Methods for modulating expression of a target gene using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of a target gene. | 2015-05-21 |
20150141321 | COMPOUND AND METHOD FOR TREATING MYOTONIC DYSTROPHY - Provided are 9-base morpholino antisense compounds targeted to polyCUG repeats in the 3′UTR region of dystrophia myotonica protein kinase (DMPK) mRNA, and related methods for treating myotonic dystrophy DM1. | 2015-05-21 |
20150141322 | THERAPEUTIC AGENT, TREATMENT METHOD AND INSPECTION METHOD FOR DISEASES CAUSED BY ACTIVATION OR NEUTROPHILS - The present invention provides a therapeutic agent, a treatment method and an inspection method for diseases caused by activation of neutrophils. More specifically, the invention relates to a neutrophil activation regulator which comprising a histidine-rich glycoprotein (HRG) as an active ingredient, and provides a therapeutic agent for diseases caused by neutrophil activation comprising the neutrophil activation regulator, a treatment method for diseases caused by neutrophil activation, and further an inspection method for diseases caused by neutrophil activation. The present invention is based on the neutrophil activation regulator including the HRG as an active ingredient. The present invention extends to the depressant agent for neutrophil-vascular endothelial cell interaction including the HRG of the present invention as an active ingredient, the treatment method for diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation. The present invention also extends to the inspection method for inflammatory diseases accompanied by neutrophil activation by measuring the blood HRG level. | 2015-05-21 |
20150141323 | PEPTIDE-OLIGOUREA CHIMERIC COMPOUNDS AND METHODS OF THEIR USE - The present description provides compositions and methods for producing therapeutic oligomeric compounds. In another aspect the description provides methods for administering the oligomeric compounds for the treatment and prevention of disease in a mammal. In particular, the invention relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the invention may optionally be administered with at least one of a pharmaceutically acceptable excipient, additional pharmacologically active agent or a combination thereof. | 2015-05-21 |
20150141324 | STABLE PEPTIDE-BASED FURIN INHIBITORS - It is provided furin inhibitors and their uses for treating pathogen infection. Particularly, it is provided a method or use for the treatment of a pathogen infection, in a subject, comprising administering to the subject a therapeutically effective amount of the furin inhibitors or the composition disclosed, thereby preventing or treating pathogen infection, in the subject. | 2015-05-21 |
20150141325 | IDENTIFICATION OF INHIBITORS OF A BACTERIAL STRESS RESPONSE - A system, a composition, a method and a kit for identifying anti-bacterial agents are provided. The invention described herein is useful in identifying inhibitors of any bacterial stress response. Moreover, the invention can be applied to any sRNA and its target, any transcription factor and its target, and any transcription factor/sRNA pair (i.e., a transcription factor that regulates a sRNA). In particular, the present invention provides a system, a composition, a method and a kit for the identification of cyclic peptides that block the σ | 2015-05-21 |
20150141326 | ANTIVIRAL COMPOUNDS - The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 2015-05-21 |
20150141327 | FIBROBLAST GROWTH FACTOR 21 VARIANTS - This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) variants, pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such variants. | 2015-05-21 |
20150141328 | STIMULATION OF HUMAN MEIBOMIAN GLAND FUNCTION - Disclosed herein are systems and methods for stimulating meibomian gland epithelial cell function by administering to the ocular surface or immediate vicinity of an eye of a subject an effective amount of a pharmaceutical composition containing a PLD-inducing compound, such as the cationic amphiphilic drugs (e.g. azithromycin), androgen or an androgen analogue with androgen effectiveness, corticosteroid, progesterone, IGF-1 or an IGF-1 analogue (e.g. insulin), GH, and mixtures thereof. The pharmaceutical compositions are effective to treat a variety of aliments to the eye including meibomian gland dysfunction, evaporative dry eye disease, lipid abnormalities in meibum or the tear film, and autoimmune diseases such as Sjögren's syndrome. | 2015-05-21 |
20150141329 | NEURTURIN MOLECULES - Neurturin polypeptides which possess reduced heparin and heparan sulfate binding affinity but retain neurotrophic activity, nucleic acids which encode the neurturin variants and vectors and host cells which express the enhanced neurturin polypeptides. Use of the enhanced neurturin polypeptides, nucleic acids and host cells in the treatment or prevention of disease. | 2015-05-21 |
20150141330 | APOLIPOPROTEIN A-I MIMICS - Provided are peptides, compositions thereof, and methods for treating or preventing dyslipidemia, a cardiovascular disease, endothelial dysfunction, a macrovascular disorder, or a microvascular disorder. | 2015-05-21 |
20150141331 | LONG-ACTING POLYPEPTIDES AND METHODS OF PRODUCING AND ADMINISTERING SAME - A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed. | 2015-05-21 |
20150141332 | METHODS FOR DIAGNOSING OSTEOARTHRITIS - Methods for managing osteoarthritis, in a human or other mammalian subject, comprising the measurement of certain cytokines and growth factors in a tissue sample of a subject, including one or more of platelet-derived growth factor AB (PDGF-AB), platelet-derived growth factor BB (PDGF-BB), and epidermal growth factor (EGF). Tissue samples may be whole blood, blood fractions, urine, saliva, and synovial fluid. Methods include diagnosing osteoarthritis, and methods for assessing the severity of osteoarthritis, such as in subject that have been diagnosed with osteoarthritis using radiographic or other methods. Methods may also include comparison of measured cytokine levels to a reference level. Methods of managing the clinical progression of osteoarthritis include initiating a clinical action based on the difference between the measured cytokine level and a reference level. | 2015-05-21 |
20150141333 | KERATIN BIOCERAMIC COMPOSITIONS - A malleable bone graft composition is described. The composition comprises: (a) keratose; (b) particulate filler; (c) antibiotic; and (d) water. The invention may be provided in sterile form in an container, and optionally lyophilized. Methods of treating a fracture with such compositions are also described. | 2015-05-21 |
20150141334 | COMPOSITION FOR INCREASING MUSCLE MASS AND A PROCESS FOR PRODUCING THE SAME - Embodiments of the present invention are related to a method for producing a composition containing biologically active follistatin. | 2015-05-21 |
20150141335 | THERAPEUTIC USES OF FIBROBLAST GROWTH FACTOR 21 PROTEINS - The present invention relates to therapeutic uses of human fibroblast growth factor 21 (FGF21) proteins. | 2015-05-21 |
20150141336 | Pancreatic Peptide Compounds and Use - The invention relates to novel use of Pancreatic Polypeptides as well as novel Pancreatic Polypeptides and compositions thereof. Such peptides can be used in treating or preventing conditions responsive to Y4 and/or Y5 receptor activation, such as cachexia. | 2015-05-21 |
20150141337 | MANUFACTURE OF DEGARELIX - The present invention provides methods for producing a lyophilized degarelix product which, upon reconstitution with water for injection in an amount of 20 mg/ml, shows a viscosity of up to 15 mPas. The present invention also provides a lyophilized degarelix drug substance which shows, upon dissolution in water in an amount of 20 mg/ml, a viscosity of up to 3.2 mPas, and processes for providing this lyophilized degarelix drug substance. | 2015-05-21 |
20150141338 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE - An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug. | 2015-05-21 |
20150141339 | TREATMENT OF OSTEOPOROSIS - According to the invention there is provided a compound of formula (I): wherein R | 2015-05-21 |
20150141340 | METHOD OF TREATING AND PREVENTING OCULAR ANGIOGENESIS - The present invention provides methods for inhibiting ocular angiogenesis, vascular leakage, and/or edema. The methods comprise administering to a subject an agent comprising a caveolin scaffolding domain. The present invention further encompasses methods of treating and/or preventing ophthalmic conditions that are associated with ocular angiogenesis, vascular leakage, or edema. | 2015-05-21 |
20150141341 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF BETA-THALASSEMIA - Methods and compositions for the treatment of β-thalassemia are provided. Methods and compositions restore or increase erythrocyte maturation in individuals afflicted with β-TM by preventing proteolysis of GATA-1 protein. Screening methods for identifying agents which bind heat shock protein 70 (HSP-70) and inhibit HSP-70 α-globin binding, but which allow GATA-1 protein-HSP-1 binding in a manner that prevents GATA-1 proteolysis. | 2015-05-21 |
20150141342 | BLOOD BORNE miRNA SIGNATURE FOR THE ACCURATE DIAGNOSIS OF PANCREATIC DUCTAL ADENOCARCINOMA - The differential expression of select miRNA in plasma and bile among patients with PDAC, chronic pancreatitis (CP), and controls were measured. Patients (n=215) with treatment-naïve PDAC (n=77), CP with bile or pancreatic duct pathology (n=67), and controls (n=71) that had been prospectively enrolled in a Pancreatobiliary Disease Biorepository at the time of endoscopic retrograde cholangiopancreatography (ERCP) or endoscopic ultrasound (EUS) were identified. Controls were patients with choledocholithiasis but normal pancreata. The sample was separated into training (n=95) and validation (n=120) cohorts to establish and then test the performance of PDAC Signature Panels in diagnosing PDAC. The training cohort (n=95) included age-matched patients with CP and controls. Panels were derived from the differential expression of 10-candidate miRNA in plasma or bile. Differential expression of miR-10b, -155, and -106b in plasma and bile accurately distinguishes individuals with PDAC from those having CP or normal pancreata. | 2015-05-21 |
20150141343 | SPARC AND METHODS OF USE THEREOF - The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor. | 2015-05-21 |
20150141344 | COMPOSITION FOR REPAIRING CARTILAGE TISSUE, METHOD FOR PRODUCING SAME, AND USE THEREOF - The present invention relates to a composition for repairing cartilage tissue, to a method for producing same, and to the use thereof. The present invention provides a composition for repairing cartilage tissue, which is obtained by mixing collagen and hyaluronic acid using a two-way syringe or a mixer, wherein the collagen has a diluted concentration of 5-60 mg/mL excepting water or a physiological phosphate buffer solution, and the hyaluronic acid has a diluted concentration of 5-20 mg/mL excepting water or a physiological phosphate buffer solution. | 2015-05-21 |
20150141345 | NOVEL COMPOUNDS AND METHODS FOR INHIBITING CELL DEATH - This invention provides novel compounds and methods for promoting cell survival and/or plasticity, especially in neuronal cells, by targeting the microtubule End Binding (EB) proteins and other associated proteins (e.g., drebrin). Methods for identifying potential modulators of cell death/plasticity are also described. | 2015-05-21 |
20150141346 | COMPOSITIONS INCLUDING TRICIRIBINE AND BORTEZOMIB AND DERIVATIVES THEREOF AND METHODS OF USE THEREOF - This application relates to combination therapies including triciribine and related compounds and bortezomib and derivatives thereof analogs and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation. | 2015-05-21 |
20150141347 | MURINE ANTI-NY-ESO-1 T CELL RECEPTORS - The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for NY-ESO-1. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a mammal and a method of treating or preventing cancer in a mammal using the inventive TCRs or related materials. | 2015-05-21 |
20150141348 | SUSTAINED RELEASE siRNA FOR OCULAR DRUG DELIVERY - The present invention provides an ocular implant comprising siRNA complexed with a transfection agent selected from the group consisting of cationic lipids and short cell penetration peptides, wherein said complex is associated with a biocompatible polymer. Said biocompatible polymer comprises a polymeric matrix configured to release said complex into the eye of a patient at therapeutic levels for a time sufficient to treat an ocular condition or disease. | 2015-05-21 |
20150141349 | Method and Composition for Alleviating Tumor Symptoms - This invention relates to methods and compositions for treating carcinoid syndrome and other adverse symptoms associated with tumor-producing neuroendocrine tumors, said methods comprising administering a therapeutically effective amount of a vascular disrupting agent, or a pharmaceutically acceptable salt thereof, to a subject having a hormone producing neuroendocrine tumor. In preferred implementations, the vascular disrupting agent is combretastatin A-4 phosphate, combretastatin A-1 diphosphate, or a pharmaceutical acceptable salt thereof. | 2015-05-21 |
20150141350 | DENDRIMER BASED NANODEVICES FOR THERAPEUTIC AND IMAGING PURPOSES - A nanodevice composition including N-acetyl cysteine linked to a dendrimer, such as a PAMAM dendrimer or a multiarm PEG polymer, is provided. Also provided is a nanodevice for targeted delivery of a compound to a location in need of treatment. The nanodevice includes a PAMAM dendrimer or multiarm PEG polymer, linked to the compound via a disulfide bond. There is provided a nanodevice composition for localizing and delivering therapeutically active agents, the nanodevice includes a PAMAM dendrimer or multiarm PEG polymer and at least one therapeutically active agent attached to the PAMAM dendrimer or multiarm PEG polymer. A method of site-specific delivery of a therapeutically active agent, by attaching a therapeutically active agent to a PAMAM dendrimer or multiarm PEG polymer using a disulfide bond, administering the PAMAM dendrimer or multiarm PEG polymer to a patient in need of treatment, localizing the dendrimer or multiarm PEG polymer to a site in need of treatment, and releasing the therapeutically active agent at the site in need of treatment. | 2015-05-21 |
20150141351 | Solid Pharmaceutical Compositions - The present invention features solid pharmaceutical compositions comprising Compound 1 (or a pharmaceutically acceptable salt thereof), Compound 2 (or a pharmaceutically acceptable salt thereof), and ritonavir (a pharmaceutically acceptable salt thereof), which are co-formulated in amorphous solid dispersion comprising a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant. | 2015-05-21 |
20150141352 | BONE LOSS PREVENTING AND BONE REGENERATION OR BONE FORMATION PROMOTING PHARMACEUTICAL COMPOSITION COMPRISING MURAMYL DIPEPTIDE - The present invention relates to a bone regeneration or bone formation promoting pharmaceutical composition comprising muramyl dipeptide, an analogue thereof, a derivative thereof or a pharmaceutically acceptable salt thereof. In contrast to existing passive therapeutic agents which center on bone absorption suppression based on mechanisms for reducing osteoclast functionality, the composition comprising muramyl dipeptide of the present invention promotes the differentiation of osteoblasts, which are bone forming cells, and can advantageously be used in various diseases where bone formation is required as an active therapeutic agent that does not affect osteoclast. | 2015-05-21 |
20150141353 | METHODS FOR TREATING HCV - This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions. | 2015-05-21 |
20150141354 | GLYCOSIDE DERIVATIVES AND USES THEREOF - This invention relates to compounds represented by formula (I): | 2015-05-21 |
20150141355 | SALACIA COMPOSITIONS, METHODS OF TREATMENT BY THEIR ADMINISTRATION, AND METHODS OF THEIR PREPARATION | 2015-05-21 |
20150141356 | Treatment of Clostridium Difficile Infection in High Risk Patients - The present invention relates to methods of preventing and/or treating | 2015-05-21 |
20150141357 | SHIKIMATE PATHWAY INHIBITORS AND THE USE THEREOF - The present invention relates to methods of inhibiting shikimate pathway, comprising administering to a subject a pharmaceutically acceptable composition comprising a compound having a formula: | 2015-05-21 |
20150141358 | REDUCED TOXICITY IN ALCOHOLIC BEVERAGES - The present invention relates to reduced toxicity of functional alcoholic beverage composition comprising distilled alcohol, deionized water, 18β-Glycyrrhizin or 18α-Glycyrrhizin and a sugar alcohol or sugars, having pH in the range of 4.0-9.0. More particularly, alcoholic beverage composition comprises distilled alcohol, deionized water, 18β-Glycyrrhizin or 18α-Glycyrrhizin and a sugar alcohol/sugars as hepato-protectants. The present invention provides an alcoholic beverage for reducing hepatotoxicity caused by its consumption and a process to manufacture the said alcoholic beverage. | 2015-05-21 |
20150141359 | Controlled Release Formulations for the Delivery of HIF-1 Inhibitors - Controlled release dosage formulations for the delivery of one or more HIF-1 inhibitors are provided. The controlled release formulations contain one or more HIF-1 inhibitors conjugated to or dispersed in a polymeric vehicle. The one or more HIF-1 inhibitors can be dispersed or encapsulated in a polymeric matrix. In some embodiments, the one or more HIF-1 inhibitors are covalently bound to a polymer, forming a polymer-drug conjugate. Polymeric vehicles can be formed into implants, microparticles, nanoparticles, or combinations thereof. Controlled release HIF-1 formulations provide prolonged therapeutic benefit while lowering side effects by releasing low levels of one or more HIF-1 inhibitors and/or HIF-1 inhibitor conjugates over a prolonged period of time. Controlled release dosage formulations can be used to treat or prevent a disease or disorder in a patient associated with vascularization, including cancer, obesity, and ocular diseases such as wet AMD. | 2015-05-21 |
20150141360 | BIOCIDAL COMPOSITIONS - A process for preparing a biocidal composition comprising the steps of: (i) dissolving at least one polyol in water to form a water/polyol co-solvent solution; (ii) adding at least one organic acid to the water/polyol co-solvent solution; (iii) adding at least one stabiliser to the water/polyol co-solvent solution; (iv) adding a flavonoid composition comprising at least one flavonoid selected from the group consisting of: poncirin, neoeriocitrin, isonaringin, rhoiflin, naringen, neodiosmin, hesperidin, neohesperidin and naringenin. | 2015-05-21 |
20150141361 | USE OF EPIGENOME-MODIFYING COMPOUNDS FOR THE TREATMENT OF GENETIC MUSCULAR DISEASES LINKED TO A PROTEIN-CONFORMATIONAL DISORDER - A pharmaceutical composition including at least one epigenome-modifying compound, for a use thereof in the treatment of genetic muscular diseases linked to a conformational disorder of at least one protein, said disorder causing the cellular degradation of the protein. | 2015-05-21 |
20150141362 | Inhibitors of Human EZH2, and Methods of Use Thereof - The invention relates to inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono- through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2, such that trimethylation of H3-K27, which is associated with certain cancers, is inhibited. The methods can be used to treat cancers including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Also provided are methods for identifying small molecule selective inhibitors of the mutant forms of EZH2 and also methods for determining responsiveness to an EZH2 inhibitor in a subject. | 2015-05-21 |
20150141363 | SUBSTITUTED NUCLEOTIDE ANALOGS - Disclosed herein are phosphorothioate nucleotide analogs, methods of synthesizing phosphorothioate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphorothioate nucleotide analogs. | 2015-05-21 |
20150141364 | COMPOSITIONS INCLUDING TRICIRIBINE AND EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR COMPOUNDS OR SALTS THEREOF AND METHODS OF USE THEREOF - This application relates to combination therapies including triciribine compounds and epidermal growth factor receptor inhibitor compounds, particularly erlotinib-like compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation. | 2015-05-21 |
20150141365 | URACYL SPIROOXETANE NUCLEOSIDES - The present invention relates to compounds of the formula I: including any possible stereoisomers thereof, wherein R | 2015-05-21 |
20150141366 | EFFECTIVE TREATMENT OF ESOPHOGEAL ADENOCARCINOMA USING TRICIRIBINE AND RELATED COMPOUNDS - The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat esophogeal adenocarcinoma by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug. | 2015-05-21 |
20150141367 | MODULATION OF GROWTH OF BIFIDOBACTERIA USING A COMBINATION OF OLIGOSACCHARIDES FOUND IN HUMAN MILK - A prebiotic formulation for oral administration to a human comprising 2′-fucosyllactose, 3′-sialyllactose and 6′-sialyllactose, and a method for modulating or stimulating the growth of Bifidobacteria in the gut. The formulation may be an infant formula. | 2015-05-21 |
20150141368 | PRESERVED COMPOSITIONS CONTAINING HYALURONIC ACID OR A PHARMACEUTICALLY-ACCEPTABLE SALT THEREOF AND RELATED METHODS - The invention provides a composition containing hyaluronic acid (HA) or a pharmaceutically-acceptable salt thereof preserved with a cationic preservative and related methods. In one embodiment, the pharmaceutically-acceptable salt is sodium hyaluronate. In another embodiment, the cationic preservative includes benzalkonium | 2015-05-21 |
20150141369 | INHIBITION OF TNF-ALPHA INDUCED ACTIVATION OF NFKB BY PENTOSAN POLYSULFATE - Oral pentosan polysulfate (PPS) compositions treat diseases such as diabetes, inflammation, atherosclerosis. The compositions are also effective in reducing matrix metalloproteinases (MMPs). | 2015-05-21 |
20150141370 | EFFICIENT PRODUCTION OF OLIGOSACCHARIDES USING METABOLICALLY ENGINEERED MICROORGANISMS - The present invention relates to the enzymatic synthesis of oligosaccharides, particularly, sialylated oligosaccharides comprising the carbohydrate moeities of the gangliosides GM3, GD3, and GT3. | 2015-05-21 |
20150141371 | METHOD OF USING NUTRITIONAL COMPOUNDS DIHYDROQUERCETIN (TAXIFOLIN) AND ARABINOGALACTAN IN COMBINATION WITH DIHYDROQUERCETIN (TAXIFOLIN) TO REDUCE AND CONTROL CARDIOMETABOLIC RISK FACTORS ASSOCIATED WITH METABOLIC SYNDROME AND HYPERCHOLESTEROLEMIA - A composition for use in a human by oral administration to reduce or control cardiometabolic risk factors associated with metabolic syndrome or hypercholesterolemia, or reduce risk of developing metabolic syndrome or hypercholesterolemia. The composition includes a combination of Arabinogalactan and Dihydroquercetin (taxifolin), where the Arabinogalactan is present in the combination as a fiber matrix in an amount higher than 70% as determined by weight on dry matter basis, and the Dihydroquercetin is present in the fiber matrix. | 2015-05-21 |
20150141372 | SUBSTITUTED CYCLOALKENOPYRAZOLES AS BUB1 INHIBITORS FOR THE TREATMENT OF CANCER - Compounds of formula (I), processes for their production and their use as Bub1 kinase inhibitors for the treatment of hyperproliferative diseases and/or disorders responsive to induction of cell death. | 2015-05-21 |
20150141373 | Osteoclast Inhibitors for Knee Conditions - Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions. | 2015-05-21 |
20150141374 | Osteoclast Inhibitors for Knee Conditions - Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions. | 2015-05-21 |
20150141375 | Methods of Treating Viral Associated Diseases - The present invention provides methods of treating diseases associated with at least one virus. The methods include administering a compound described in the invention in a therapeutically effective amount. According to some aspects of the present invention, the methods may further comprise at least one immunosuppressant agent to treat diseases associated with at least one virus of a subject in need of immunosuppressant agents. | 2015-05-21 |
20150141376 | Pharmaceutical compositions of anti-viral compounds and process for preparation thereof - Pharmaceutical compositions of anti-viral compounds, process for preparation and method of using the same are provided. Particularly, the present invention relates to chemically stable pharmaceutical compositions of efavirenz, emtricitabine and tenofovir disoproxil fumarate with optionally one or more pharmaceutically acceptable excipients, process for preparation and method for the treatment or prevention of the symptoms or effects of an HIV infection in an infected patient. | 2015-05-21 |
20150141377 | SYNERGISTIC COMPOSITION - A synergistic composition comprising a THP salt and a biopenetrant, in which the biopenetrant comprises a polymer of an unsaturated carboxylic acid or a copolymer of an unsaturated carboxylic acid with a sulphonic acid, said polymer or copolymer being terminated by a mono- or diphosphonated unsaturated carboxylic acid group or having such monomers incorporated into the polymer backbone. This composition acts synergistically to enhance the biocidal efficacy of the THP salt against both planktonic (free-swimming) and sessile (attached) bacteria, and also acts synergistically to enhance the efficacy of the THP salt in the dissolution of iron sulphide scale. | 2015-05-21 |
20150141378 | NITROXYL PROGENITOR COMPOUNDS AND METHODS OF USE - Described herein are nitroxyl progenitor compounds, and compositions including, and methods or generating, the compounds thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions. | 2015-05-21 |
20150141379 | TIGECYCLINE COMPOSITIONS AND METHODS OF PREPARATION - The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer. | 2015-05-21 |
20150141380 | INHIBITORS OF ERK FOR DEVELOPMENTAL DISORDERS OF NEURONAL CONNECTIVITY - A method of treating a subject at risk of or suspected of having Fragile X syndrome or autism spectrum disorder associated with abnormalities of ERK includes administering to the subject a therapeutically effective amount of at least one ERK inhibiting compound that prevents abnormalities in neuronal connectivity, a prodrug thereof that is metabolisable to form the compound, or a pharmaceutically acceptable salt thereof. | 2015-05-21 |
20150141381 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES - Methods and compounds for treating diseases with tetracycline compounds having a target therapeutic activity are described. | 2015-05-21 |
20150141382 | NOVEL SOLVATES OF DARUNAVIR - The present invention relates to novel solvates of Darunavir of Formula I. | 2015-05-21 |
20150141383 | Darunavir Polymorph and Process for Preparation Thereof - There is disclosed crystalline darunavir hydrate substantially free of any non-aqueous solvent. | 2015-05-21 |
20150141384 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DEGENERATIVE DISORDERS - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I; and methods for treating or preventing neurological degenerative disorders, may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of Alzheimer's disease, Lewy body disease, Huntington's disease, Amyotrophic lateral sclerosis (ALS) and Parkinson's disease. | 2015-05-21 |
20150141385 | Methods Useful for Vitamin D Deficiency and Related Disorders - Methods for diagnosing, treating, and preventing catabolism-related vitamin D deficiency and related disorders, related compositions, apparatus and kits, are disclosed. A method involves measuring CYP24 expression and/or activity, or a proxy thereof such as FGF23 level, in a patient and correlating abnormally elevated CYP24 expression and/or activity with catabolism-related vitamin D deficiency or with susceptibility for catabolism-related vitamin D deficiency. In response to abnormally elevated CYP24 expression and/or activity, the method further includes administering a CYP24 inhibitor to the vitamin D deficient or at-risk patient, and preferably avoiding activation of the vitamin D binding receptor, such as by avoiding administration of active vitamin D compounds to such patients. Optionally, a vitamin D prohormone or prohormone can be administered. | 2015-05-21 |
20150141386 | USE OF VITAMIN K TO DECREASE ALLOGRAFT FAILURE AND PATIENT MORTALITY AFTER ORGAN TRANSPLANTATION - Poor vitamin K status is provided as an independent risk factor for allograft failure and mortality in patients who received organ transplantation and who are under immunosuppressive medication. Various forms and recommended dosages of vitamin K, optionally combined with vitamin D and/or other immunosuppressive medication, are provided to optimize the treatment of such patients resulting in decreased allograft failure and improved patient survival. | 2015-05-21 |
20150141387 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT - The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is N-Cyclopropyl-3-fluoro-4-methyl-5-[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxo-1(2H)-pyrazinyl]-benzamide or a salt thereof, and a second active ingredient selected from: a non-steroidal Glucocorticoid Receptor (GR Receptor) Agonist; an antioxidant; a β2 adrenoceptor agonist; a CCR1 antagonist; a chemokine antagonist (not CCR1); a corticosteroid; a CRTh2 antagonist; a DPI antagonist; an Histone Deacetylase activator; an IKK2 kinase inhibitor; a COX inhibitor; a lipoxygenase inhibitor; a leukotriene receptor antagonist; a MABA compound; an MPO inhibitor; a muscarinic antagonist; a PDE4 inhibitor; a PPARγ agonist; a protease inhibitor; a Statin; a thromboxane antagonist; a vasodilator; or, an ENAC blocker (Epithelial Sodium-channel blocker); and its use in the treatment of respiratory disease. | 2015-05-21 |
20150141388 | DELAYED-RELEASE GLUCOCORTICOID TREATMENT OF RHEUMATOID DISEASE - The present invention refers to the treatment of a rheumatic disease and/or osteoarthritis by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof. | 2015-05-21 |
20150141389 | Topical Formulation Compositions Containing Silicone Based Excipients To Deliver Actives To A Substrate - The present disclosure relates to a semi-solid topical drug delivery formulation including a silicone-based excipient, at least one volatile solvent, at least one active configured to be topically delivered through a patient's skin for an intended therapeutic application, and at least one enhancer. The formulation may additionally optionally include at least one agent that provides occlusivity when the formulation is applied onto a patient's skin. The at least one active may be a healthcare and/or pharmaceutical active. | 2015-05-21 |
20150141390 | PLANT STEROIDS AND USES THEREOF - The invention relates to a drug conjugate including a drug and a plant steroid. The drug conjugate may target the drug for intestinal cell delivery, and thus may be used to treat diseases, including intestinal diseases, or to affect intestinal metabolism. The invention therefore also relates to treating intestinal diseases and affecting intestinal metabolism with the drug conjugate. | 2015-05-21 |
20150141391 | SYSTEMS AND METHODS FOR DETERMINING A TREATMENT COURSE OF ACTION - The present disclosure relates to methods of determining a treatment course of action. In particular, the present disclosure relates to mutations in the gene encoding estrogen receptor and their association with responsiveness to estrogen therapies for cancer. | 2015-05-21 |
20150141392 | SUBSTITUTED MACROCYCLIC COMPOUNDS HAVING PROTEASOME INHIBITORY ACTIVITY - The disclosure provides for novel compounds which have proteasome inhibitory activity, pharmaceutical compositions made thereof, and methods of use thereof to treat various disorders, including cancer and nonmalignant tumors. | 2015-05-21 |
20150141393 | ENHANCED PRESERVATIVE - A composition having biocidal properties is disclosed. The composition includes a first biocide, optionally a second biocide, and a biocide enhancing agent. The first biocide may comprise an isothiazolin. The second biocide may comprise a pyrithione. The biocide enhancing agent may comprise an amine, an amine salt, an amine oxide, or mixtures thereof. The amine compound may have a carbon chain length of at least six carbon atoms, such as at least eight carbon atoms. | 2015-05-21 |
20150141394 | NITROGEN CONTAINING COMPOUNDS AND THEIR USE - Compounds of Formula (I), their preparation and use in preventing or treating bacterial infections are disclosed. | 2015-05-21 |